Search

Your search keyword '"Blandamura, Stella"' showing total 10 results
Start Over Author "Blandamura, Stella" Journal american journal of otolaryngology
10 results on '"Blandamura, Stella"'

1. Expression of maspin tumor suppressor and mTOR in laryngeal carcinoma

Author

Marioni, Gino, primary, Ottaviano, Giancarlo, additional, Lovato, Andrea, additional, Franz, Leonardo, additional, Bandolin, Luigia, additional, Contro, Giacomo, additional, Giacomelli, Luciano, additional, Alessandrini, Lara, additional, Stramare, Roberto, additional, de Filippis, Cosimo, additional, and Blandamura, Stella, additional

Published
2020
Full Text
View/download PDF

4. Silver sucrose octasulfate nasal applications and wound healing after endoscopic sinus surgery: a prospective, randomized, double-blind, placebo-controlled study

Author

Ottaviano, Giancarlo, primary, Blandamura, Stella, additional, Fasanaro, Elena, additional, Favaretto, Niccolo’, additional, Andrea, Lovato, additional, Giacomelli, Luciano, additional, Bartolini, Andrea, additional, Staffieri, Claudia, additional, Marchese-Ragona, Rosario, additional, Marioni, Gino, additional, and Staffieri, Alberto, additional

Published
2015
Full Text
View/download PDF

6. Cortactin and phosphorylated cortactin tyr466 expression in temporal bone carcinoma.

Author

Marioni, Gino, Zanoletti, Elisabetta, Mazzoni, Antonio, Gianatti, Andrea, Valentini, Elisa, Girasoli, Laura, Guariento, Martina, Giacomelli, Luciano, Martini, Alessandro, and Blandamura, Stella

Abstract

Purpose: Cortactin is a multidomain protein engaged in several cellular mechanisms involving actin assembly and cytoskeletal arrangement. Cortactin overexpression in several malignancies has been associated with increased cell migration, invasion, and metastatic potential. Cortactin needs to be activated by tyrosine or serine/threonine phosphorylation. The role of cortactin and phosphorylated cortactin (residue tyr466) was investigated in temporal bone squamous cell carcinoma (TBSCC).Materials and Methods: Immunohistochemical expression of cortactin and phosphorylated cortactin (residue tyr466) was assessed in 27 consecutively-operated TBSCCs.Results: Several clinicopathological variables correlated with recurrence (pT stage, dura mater involvement), and disease-free survival (DFS) (cT stage, pT stage, pN status, dura mater involvement). Twenty-three of 24 immunohistochemically evaluable TBSCCs were cortactin-positive. Median cortactin expression was 75.0%. Cortactin reaction in the cytoplasm was more intense in carcinoma cells than in normal adjacent tissue. Recurrence and DFS rates did not correlate with cortactin and phosphorylated cortactin (residue tyr466) expression in TBSCC specimens.Conclusions: Cortactin upregulation in TBSCC supports the conviction that inhibiting cortactin functions could have selective effects on this malignancy. Multi-institutional studies should further investigate the role of cortactin and phosphorylated cortactin in TBSCC, and their potential clinical application in integrated treatment modalities. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results